LIUZHOU CITY, China, May 11 /PRNewswire-Asia/ -- China Baicaotang Medicine Ltd. (OTC Bulletin Board: CNBI) ("CBT," or the "Company"), a provincial leader in pharmaceutical distribution and retailing in the Guangxi Province of China announced today that Harbinger Research, LLC, an independent equity research firm, will provide research coverage on the Company.
Mr. Tang Hui Tian, Chairman and CEO of CBT, stated that "Our Company is in the midst of growth and expansion in Guangxi province, and given our status as a U.S.-traded Company and plans to up-list to a national exchange in the near future, we feel Harbinger Research's coverage of CBT comes at an excellent time for CBT and its investors. We believe our company and industry will continue to demonstrate robust growth for years to come, as per-capita disposable income and government-driven pharmaceutical spending in China continue to grow."
Brian R. Connell, CFA, a Harbinger Research Senior Analyst, stated that, "We are excited to initiate coverage on China Baicaotang, which we believe is significantly undervalued on both a relative and absolute basis. We expect the pharmaceutical industry to remain strong in China for the foreseeable future, clearly benefiting all provincial industry leaders, including China Baicaotang."
To view Harbinger Research's coverage initiation on China Baicaotang Medicine, Ltd., rated by Brian R. Connell, CFA, please click on the following link: http://www.harbingerresearch.com/link/13/253/CNBI
About China Baicaotang Medicine, Ltd.
China Baicaotang is a vertically-integrated pharmaceutical company that operates in the Guangxi Province of China. The Company's three operating subsidiaries include a drug and herbal remedy manufacturing company, a pharmaceutical distributor that carries over 8,000 products, and a retail drugstore chain with 66 stores throughout the Guangxi province. The company is an emerging leader in this region of the PRC, and its shares currently traded on the OTC:BB under the symbol CNBI. Learn more http://www.china-bct.com .
About Harbinger Research, LLC
Harbinger Research is an independent equity research that employs a research team consisting entirely of CFA charter holders and follows a number of companies across a wide variety of industries. Harbinger Research makes all of its reports available through its website at http://www.harbingerresearch.com , and also distributes content through a variety of partners, including InvestorsInsight Publishing, and through most major financial portals.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.
For more information, please contact:
China Baicaotang Medicine, Ltd. Investor Contact:
Shelly Zhang
Chief Financial Officer
China Baicaotang Medicine Limited
Email: z_shelly@hotmail.com
Tel: +86-772-363-8318
Web: http://www.china-bct.com